Landmark Series A round positions Australian biotech at the forefront of neurodegenerative disease innovation.
Landmark Series A round positions Australian biotech at the forefront of neurodegenerative disease innovation.
With a fresh $153 million in funding, Strand Therapeutics is pushing the boundaries of mRNA technology—this time, in …
AI-driven drug discovery is accelerating innovation and transforming biopharma R&D.
ExoGene’s novel delivery platform earns RMAT status for its lead candidate EXG-401, targeting neuroinflammation and motor neuron survival …
Already a subscriber? Log in